Loading...

AVEO Pharmaceuticals

DB:VPA
Snowflake Description

High growth potential and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
VPA
DB
$162M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. The last earnings update was 38 days ago. More info.


Add to Portfolio Compare Print
  • AVEO Pharmaceuticals has significant price volatility in the past 3 months.
VPA Share Price and Events
7 Day Returns
11.2%
DB:VPA
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-54.6%
DB:VPA
-10.2%
DE Biotechs
-6%
DE Market
VPA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
AVEO Pharmaceuticals (VPA) 11.2% 79.5% -43.1% -54.6% 9.7% 1.3%
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • VPA underperformed the Biotechs industry which returned -10.2% over the past year.
  • VPA underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
VPA
Industry
5yr Volatility vs Market

Value

 Is AVEO Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of AVEO Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for AVEO Pharmaceuticals.

DB:VPA Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.5%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:VPA
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 21%) (11.72%))
1.39
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.39
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.39 * 5.96%)
8.51%

Discounted Cash Flow Calculation for DB:VPA using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for AVEO Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:VPA DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.51%)
2019 -30.50 Analyst x1 -28.11
2020 -28.30 Analyst x1 -24.03
2021 -4.90 Analyst x1 -3.84
2022 -0.70 Analyst x1 -0.50
2023 80.30 Analyst x1 53.38
2024 145.37 Est @ 81.03% 89.05
2025 227.93 Est @ 56.79% 128.67
2026 318.69 Est @ 39.82% 165.80
2027 407.75 Est @ 27.94% 195.49
2028 487.79 Est @ 19.63% 215.52
Present value of next 10 years cash flows $791.41
DB:VPA DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $487.79 × (1 + 0.23%) ÷ (8.51% – 0.23%)
$5,902.29
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $5,902.29 ÷ (1 + 8.51%)10
$2,607.81
DB:VPA Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $791.41 + $2,607.81
$3,399.22
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $3,399.22 / 160.74
$21.15
DB:VPA Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:VPA represents 0.95247x of NasdaqCM:AVEO
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.95247x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 21.15 x 0.95247
€20.14
Value per share (EUR) From above. €20.14
Current discount Discount to share price of €0.96
= -1 x (€0.96 - €20.14) / €20.14
95.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price AVEO Pharmaceuticals is available for.
Intrinsic value
>50%
Share price is €0.96 vs Future cash flow value of €20.14
Current Discount Checks
For AVEO Pharmaceuticals to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • AVEO Pharmaceuticals's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • AVEO Pharmaceuticals's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for AVEO Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are AVEO Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:VPA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.04
NasdaqCM:AVEO Share Price ** NasdaqCM (2019-04-18) in USD $1.01
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of AVEO Pharmaceuticals.

DB:VPA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:AVEO Share Price ÷ EPS (both in USD)

= 1.01 ÷ -0.04

-22.86x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AVEO Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • AVEO Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does AVEO Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:VPA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -22.86x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
32.8%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for AVEO Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on AVEO Pharmaceuticals's assets?
Raw Data
DB:VPA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $-0.22
NasdaqCM:AVEO Share Price * NasdaqCM (2019-04-18) in USD $1.01
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:VPA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:AVEO Share Price ÷ Book Value per Share (both in USD)

= 1.01 ÷ -0.22

-4.69x

* Primary Listing of AVEO Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • AVEO Pharmaceuticals has negative assets, we can't compare the value of its assets to the DE Biotechs industry average.
X
Value checks
We assess AVEO Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. AVEO Pharmaceuticals has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is AVEO Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
32.8%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is AVEO Pharmaceuticals expected to grow at an attractive rate?
  • AVEO Pharmaceuticals's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • AVEO Pharmaceuticals's earnings growth is expected to exceed the Germany market average.
  • AVEO Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:VPA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:VPA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts 32.8%
DB:VPA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 56.9%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:VPA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:VPA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 175 25 3
2022-12-31 66 -12 3
2021-12-31 46 -19 3
2020-12-31 15 -27 5
2019-12-31 10 -28 5
DB:VPA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 5 -25 -5
2018-09-30 4 -22 -24
2018-06-30 6 -22 -28
2018-03-31 6 -20 -65
2017-12-31 8 -19 -65
2017-09-30 8 -23 -74
2017-06-30 4 -29 -53
2017-03-31 4 -26 -28
2016-12-31 3 -31 -27
2016-09-30 6 -24 -28
2016-06-30 20 -6 -15
2016-03-31 20 -13 -12

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • AVEO Pharmaceuticals's earnings are expected to grow significantly at over 20% yearly.
  • AVEO Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:VPA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from AVEO Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:VPA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.07 0.29 -0.12 4.00
2022-12-31 -0.08 0.01 -0.16 4.00
2021-12-31 -0.09 -0.02 -0.15 4.00
2020-12-31 -0.14 -0.10 -0.18 5.00
2019-12-31 -0.17 -0.09 -0.20 5.00
DB:VPA Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.04
2018-09-30 -0.20
2018-06-30 -0.24
2018-03-31 -0.56
2017-12-31 -0.61
2017-09-30 -0.78
2017-06-30 -0.62
2017-03-31 -0.38
2016-12-31 -0.39
2016-09-30 -0.43
2016-06-30 -0.25
2016-03-31 -0.21

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if AVEO Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess AVEO Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
AVEO Pharmaceuticals has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has AVEO Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare AVEO Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • AVEO Pharmaceuticals does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare AVEO Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare AVEO Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
AVEO Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from AVEO Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:VPA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 5.41 -5.33 10.78
2018-09-30 4.01 -23.65 10.56
2018-06-30 6.16 -27.88 9.94
2018-03-31 6.07 -65.17 9.42
2017-12-31 7.58 -65.03 9.14
2017-09-30 7.62 -74.13 8.60
2017-06-30 4.00 -52.70 8.64
2017-03-31 3.84 -28.02 8.07
2016-12-31 2.52 -26.89 8.21
2016-09-30 5.99 -27.87 9.99
2016-06-30 20.15 -14.99 10.08
2016-03-31 20.09 -11.84 11.23
2015-12-31 19.02 -15.00 10.22
2015-09-30 15.54 -22.31 10.57
2015-06-30 1.26 -44.66 13.43
2015-03-31 2.97 -57.16 15.39
2014-12-31 18.12 -52.74 18.59
2014-09-30 18.33 -55.57 19.98
2014-06-30 17.78 -65.44 19.34
2014-03-31 16.26 -79.39 21.82
2013-12-31 1.29 -107.03 28.71
2013-09-30 16.50 -111.78 33.68
2013-06-30 17.20 -117.60 38.54
2013-03-31 18.75 -115.23 40.40
2012-12-31 19.29 -114.39 36.93
2012-09-30 4.85 -118.05 34.46
2012-06-30 7.42 -111.71 31.74 -61.75

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if AVEO Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if AVEO Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if AVEO Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess AVEO Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
AVEO Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is AVEO Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up AVEO Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • AVEO Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • AVEO Pharmaceuticals's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of AVEO Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • AVEO Pharmaceuticals has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from AVEO Pharmaceuticals Company Filings, last reported 3 months ago.

DB:VPA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 -27.23 19.03 24.43
2018-09-30 -60.39 18.88 20.41
2018-06-30 -45.45 18.73 18.09
2018-03-31 -50.25 18.59 27.00
2017-12-31 -40.76 18.48 33.53
2017-09-30 -44.57 19.24 37.41
2017-06-30 -19.33 19.12 40.13
2017-03-31 4.91 14.14 33.41
2016-12-31 -1.92 14.00 23.35
2016-09-30 3.54 13.87 30.83
2016-06-30 8.29 13.74 39.53
2016-03-31 9.92 9.56 23.81
2015-12-31 17.23 9.47 34.14
2015-09-30 23.88 12.48 37.24
2015-06-30 11.24 15.30 26.77
2015-03-31 14.59 18.02 39.07
2014-12-31 20.61 20.65 52.31
2014-09-30 34.27 20.45 63.39
2014-06-30 46.96 14.18 64.94
2014-03-31 64.27 16.73 88.32
2013-12-31 69.94 19.21 118.51
2013-09-30 85.81 21.59 130.36
2013-06-30 108.91 23.89 156.17
2013-03-31 141.18 26.12 191.63
2012-12-31 118.94 26.04 160.60
2012-09-30 138.19 25.96 189.69
2012-06-30 165.83 25.88 215.89
  • AVEO Pharmaceuticals has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if AVEO Pharmaceuticals's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • AVEO Pharmaceuticals has less than a year of cash runway based on current free cash flow.
  • AVEO Pharmaceuticals has less than a year of cash runway if free cash flow continues to grow at historical rates of 11.9% each year.
X
Financial health checks
We assess AVEO Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. AVEO Pharmaceuticals has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is AVEO Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from AVEO Pharmaceuticals dividends.
If you bought €2,000 of AVEO Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate AVEO Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate AVEO Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:VPA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:VPA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as AVEO Pharmaceuticals has not reported any payouts.
  • Unable to verify if AVEO Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of AVEO Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as AVEO Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess AVEO Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can AVEO Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. AVEO Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of AVEO Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Michael Bailey
COMPENSATION $1,368,658
AGE 53
TENURE AS CEO 4.3 years
CEO Bio

Mr. Michael P. Bailey has been Chief Executive Officer and President of AVEO Pharmaceuticals, Inc. since January 7, 2015 and served as its Secretary. Mr. Bailey served as the Principal Financial Officer of AVEO Pharmaceuticals, Inc. until April 2015. He served as Chief Business Officer of AVEO Pharmaceuticals, Inc. since June 2013 and as its Chief Commercial Officer from September 2010 to June 2013. He served as the Chief Commercial Officer and Senior Vice President, Business Development of Synta Pharmaceuticals Corp. from August 4, 2008 to September 7, 2010. He served as Senior Vice President of Commercial Operations at ImClone Systems Corporation from August 2, 2006 to August 1, 2008 and Vice President of Marketing since January 2003. Mr. Bailey has more than 16 years of executive and operational experience in the pharmaceutical and biotech industries, with nearly a decade dedicated to oncology. Since 1999, he held leadership positions of increasing responsibility at ImClone Systems Incorporated. He led ImClone's Worldwide Commercial Organization, responsible for commercial aspects for the planning and launch of Erbitux(R) across multiple indications. Mr. Bailey was a key member of the strategic leadership committees for ImClone and its North American and Worldwide partnerships. He served at Genentech, Inc from 1997 to 1999. where he managed its cardiovascular development portfolio. He serves as a Director of AVEO Pharmaceuticals, Inc. since January 2015. He started his career in the pharmaceutical industry as one of two MBA graduates selected for Smith-Kline Beecham's Executive Marketing Development Program, where he held a variety of commercial roles, including sales, strategic planning and product management from 1992 to 1997. Mr. Bailey earned a BS in Psychology and also his MBA in International Marketing by graduating with honors from both St. Lawrence University and the University of Notre Dame Graduate School of Business.

CEO Compensation
  • Michael's compensation has increased whilst company is loss making.
  • Michael's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the AVEO Pharmaceuticals management team in years:

3.8
Average Tenure
53
Average Age
  • The tenure for the AVEO Pharmaceuticals management team is about average.
Management Team

Michael Bailey

TITLE
CEO, President & Director
COMPENSATION
$1M
AGE
53
TENURE
4.3 yrs

Matt Dallas

TITLE
Chief Financial Officer
COMPENSATION
$1M
AGE
43
TENURE
1.8 yrs

Mike Needle

TITLE
Chief Medical Officer
COMPENSATION
$813K
AGE
58
TENURE
4.3 yrs

Nikhil Mehta

TITLE
Senior Vice President of Regulatory & Quality Assurance
COMPENSATION
$1M
AGE
59
TENURE
1.4 yrs

Emile Farhan

TITLE
Vice President of Technical Operations

Karuna Rubin

TITLE
Senior VP & General Counsel
AGE
41
TENURE
3.8 yrs
Board of Directors Tenure

Average tenure and age of the AVEO Pharmaceuticals board of directors in years:

10.5
Average Tenure
69
Average Age
  • The average tenure for the AVEO Pharmaceuticals board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Michael Bailey

TITLE
CEO, President & Director
COMPENSATION
$1M
AGE
53
TENURE
4.3 yrs

Tony Evnin

TITLE
Director
COMPENSATION
$53K
AGE
77
TENURE
17.1 yrs

Ken Bate

TITLE
Director
COMPENSATION
$68K
AGE
68
TENURE
11.3 yrs

Robert Young

TITLE
Director
COMPENSATION
$49K
AGE
78
TENURE
9.8 yrs

Raju Kucherlapati

TITLE
Member of Scientific Advisory Board
COMPENSATION
$3K
AGE
75

Tyler Jacks

TITLE
Member of Scientific Advisory Board
AGE
57

H. Horvitz

TITLE
Member of Scientific Advisory Board

Lynda Chin

TITLE
Member of Scientific Advisory Board

Lewis Cantley

TITLE
Member of Scientific Advisory Board
AGE
69

Douglas Hanahan

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
08. Apr 19 Buy New Enterprise Associates Company 08. Apr 19 08. Apr 19 4,347,827 €1.01 €4,401,888
22. Dec 18 Buy New Enterprise Associates Company 20. Dec 18 21. Dec 18 500,000 €1.43 €678,564
12. Dec 18 Buy New Enterprise Associates Company 11. Dec 18 11. Dec 18 61,200 €1.75 €106,929
10. Dec 18 Buy New Enterprise Associates Company 06. Dec 18 10. Dec 18 170,400 €1.75 €297,648
30. Nov 18 Buy New Enterprise Associates Company 28. Nov 18 30. Nov 18 96,400 €1.76 €168,595
26. Nov 18 Buy VR Adviser, LLC Company 21. Nov 18 21. Nov 18 109 €1.80 €196
21. Nov 18 Buy New Enterprise Associates Company 20. Nov 18 20. Nov 18 170,000 €1.73 €294,934
20. Nov 18 Buy New Enterprise Associates Company 15. Nov 18 19. Nov 18 1,200,000 €1.64 €1,953,972
16. Nov 18 Sell VR Adviser, LLC Company 14. Nov 18 16. Nov 18 -1,147,068 €1.67 €-1,877,028
22. Aug 18 Buy New Enterprise Associates Company 21. Aug 18 21. Aug 18 663,716 €1.96 €1,301,398
20. Jul 18 Buy New Enterprise Associates Company 18. Jul 18 19. Jul 18 250,600 €1.72 €423,884
28. Jun 18 Buy New Enterprise Associates Company 27. Jun 18 28. Jun 18 192,425 €1.86 €348,678
30. May 18 Buy New Enterprise Associates Company 30. May 18 30. May 18 275 €1.85 €508
21. May 18 Buy New Enterprise Associates Company 17. May 18 21. May 18 236,479 €1.82 €428,111
10. May 18 Buy New Enterprise Associates Company 08. May 18 08. May 18 70,873 €1.80 €127,489
X
Management checks
We assess AVEO Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. AVEO Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC). The company has also completed a Phase 3 TIVO-3 trial of tivozanib for the treatment of RCC; and initiated enrollment in a phase Ib/II clinical trial of tivozanib in combination with Opdivo (nivolumab), an immune checkpoint (PD-1) inhibitor, for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent hepatocyte growth factor inhibitory antibody for the treatment of squamous cell carcinoma of the head and neck, metastatic pancreatic ductal cancer, and acute myeloid leukemia; and AV-203, a potent anti-ErbB3 specific monoclonal antibody, which has completed Phase I clinical trial for treating esophageal cancer. The company’s preclinical stage products include AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and AV-353 for the treatment of pulmonary arterial hypertension. It has strategic partnerships with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent’s Hospital Sydney Limited; Biogen Idec; and Kyowa Hakko Kirin Co., Ltd. AVEO Pharmaceuticals, Inc. has a clinical collaboration with AstraZeneca PLC to evaluate IMFINZI (durvalumab), a human monoclonal antibody directed against programmed death-ligand 1 (PD-L1). The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is based in Cambridge, Massachusetts.

Details
Name: AVEO Pharmaceuticals, Inc.
VPA
Exchange: DB
Founded: 2001
$144,358,832
160,739,471
Website: http://www.aveooncology.com
Address: AVEO Pharmaceuticals, Inc.
One Broadway,
14th Floor,
Cambridge,
Massachusetts, 02142,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM AVEO Common Stock Nasdaq Capital Market US USD 12. Mar 2010
DB VPA Common Stock Deutsche Boerse AG DE EUR 12. Mar 2010
LSE 0HJQ Common Stock London Stock Exchange GB USD 12. Mar 2010
Number of employees
Current staff
Staff numbers
17
AVEO Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:17
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/08
Last earnings filing: 2019/03/14
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.